Spontaneous Reporting Systems for Adverse Drug Reactions
Spontaneous Reporting Systems (SRS) are a cornerstone of post-marketing drug safety surveillance. Healthcare professionals and patients voluntarily submit reports of suspected adverse drug reactions (ADRs) to a central database. While subject to under-reporting and bias, these systems are crucial for detecting rare, unexpected, or long-latency ADRs that may not be identified during pre-market clinical trials.
Spontaneous Reporting Systems (SRS) form the foundation of passive surveillance in pharmacovigilance. The core principle is the unsolicited reporting of suspected adverse events by individuals, primarily healthcare providers but increasingly patients themselves. The UK’s Yellow Card Scheme, launched in 1964, is one of the earliest and most well-known examples. In the United States, the FDA Adverse Event Reporting System (FAERS) serves a similar function.
The primary strength of SRS is its broad scope. It can collect data on all drugs and all patients for an indefinite period, making it an invaluable tool for identifying safety issues that are too rare to be detected in the relatively small and controlled environment of pre-approval clinical trials. These systems are particularly effective at detecting ‘Type B’ (bizarre) adverse reactions, which are not related to the drug’s known pharmacological action.
However, SRS has significant limitations. The most critical is under-reporting; it is estimated that only a small fraction of all ADRs are ever reported. The data quality can be inconsistent, often lacking detailed clinical information. Furthermore, because there is no systematic data collection, it is impossible to calculate the incidence rate of an ADR, as the total number of patients exposed to the drug (the denominator) is unknown. Reports are also subject to various biases, such as notoriety of a drug leading to increased reporting (stimulated reporting). Despite these weaknesses, SRS remains an indispensable, cost-effective method for generating safety signals that can then be investigated using more rigorous epidemiological studies.
UNESCO Nomenclature: 3211
– Public Health
Precursors
- the thalidomide tragedy highlighting the need for post-marketing surveillance
- the establishment of national health services and regulatory bodies
- advances in database technology and data management
- the tradition of medical case reporting in journals
Applications
- signal detection for new adverse drug reactions
- informing regulatory actions like label changes or drug withdrawal
- generating hypotheses for further pharmacoepidemiological studies
- populating global databases like VigiBase
- monitoring the safety of vaccines (e.g., VAERS in the US)
Potential Innovations Ideas
Due to scrapping bot traffic, currently more than 40k per day, this content is reserved to community members.
> Login < or > Register < (100% free) to access this, so as all other restricted content and tools.
Related to: spontaneous reporting system, SRS, adverse drug reaction, ADR, pharmacovigilance, post-marketing surveillance, signal detection, Yellow Card Scheme, FAERS, under-reporting.